Please login to the form below

Not currently logged in
Email:
Password:

Lovaza

This page shows the latest Lovaza news and features for those working in and with pharma, biotech and healthcare.

FDA okays Amarin’s Vascepa for cardiovascular risk reduction

FDA okays Amarin’s Vascepa for cardiovascular risk reduction

It’s also a remarkable achievement as generics of GlaxoSmithKline’s rival fish oil therapy Lovaza (omega-3-acid ethyl esters capsules) were unable to show a similar cardiovascular benefit in

Latest news

  • GSK holds on to older products GSK holds on to older products

    No suitable buyer found for portfolio of established medicines. Lovaza is one of several of GSK's drugs in its established products portfolio. ... The decline was primarily due to the onset of generic competition for the company's fish oil drug Lovaza,

  • FDA approves AZ’s fish oil drug FDA approves AZ’s fish oil drug

    Once launched Epanova will enter a competitive for market for hypertriglyceridemia medicines, including BASF/Pronova's Omacor/Lovaza, another omega-3 fatty acid product. ... Omacor/Lovaza achieved end-user sales of around $1.4bn in 2011 and is sold by

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Israel-based Teva Pharmaceutical Industries has won US FDA approval for a generic equivalent to GlaxoSmithKline's fish-oil derived cardiovascular product Lovaza and will launch it immediately. ... GSK acquired US rights to Lovaza - which was originally

  • GSK starts recovery from China crisis as growth returns GSK starts recovery from China crisis as growth returns

    That prediction disappointed some analysts, although it is thought to be a conservative estimate based on potential generic competition to older products such as cardiovascular drug Lovaza (omega-3-acid ethyl

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    One of the claims made by Amarin for Vascepa is that it reduces triglycerides without raising LDL-C, which could differentiate it from Lovaza/Omacor (omega-3-acid ethyl esters), another ... Lovaza sales in the first half of this year were around $500m

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2012 Pharma deals during November 2012

    a cash buyout valued at $845m. Pronova supplies the active ingredient in GSK's triglyceride lowering omega-3 drug Lovaza and, in addition, is developing competitor formulations – the most advanced being ... 900. Pronova BioPharma / BASF. Acquisition.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics